Fortress Biotech Files 8-K for Corporate Changes

TL;DR

FBIO filed an 8-K for corporate changes on 6/19, check exhibits for details.

AI Summary

Fortress Biotech, Inc. filed an 8-K on June 25, 2024, reporting a change in its corporate structure or bylaws as of June 19, 2024. The filing also includes financial statements and exhibits. The company, incorporated in Delaware, is involved in the pharmaceutical preparations industry.

Why It Matters

This filing indicates potential internal corporate adjustments or strategic shifts within Fortress Biotech, which could impact its operational structure and future reporting.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not appear to involve significant financial events or strategic shifts that would immediately impact the company's risk profile.

Key Players & Entities

• Fortress Biotech, Inc. (company) — Registrant
• June 19, 2024 (date) — Earliest event date
• June 25, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of Incorporation
• PHARMACEUTICAL PREPARATIONS (industry) — Standard Industrial Classification

FAQ

Filing Documents

• fbio-20240619x8k.htm (8-K) — 38KB
• fbio-20240619xex3d1.htm (EX-3.1) — 102KB
• fbio-20240619xex3d2.htm (EX-3.2) — 78KB
• 0001558370-24-009466.txt ( ) — 413KB
• fbio-20240619.xsd (EX-101.SCH) — 4KB
• fbio-20240619_def.xml (EX-101.DEF) — 15KB
• fbio-20240619_lab.xml (EX-101.LAB) — 17KB
• fbio-20240619_pre.xml (EX-101.PRE) — 15KB
• fbio-20240619x8k_htm.xml (XML) — 7KB

03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year . On June 19, 2024, the Board of Directors (the "Board") of Fortress Biotech, Inc. (the "Company") adopted the Fourth Amended and Restated Bylaws of the Company (the "Amended Bylaws"), effective immediately. The Amended Bylaws modify the Company's prior bylaws to (i) change the voting requirement for the election of directors at meetings of the stockholders of the Company in uncontested elections to a vote of a majority of the votes cast for the election of each director and to change the voting requirement for the election of directors at meetings of the stockholders of the Company in contested elections to a plurality of the votes cast for the election of each director, (ii) require any director who does not receive the affirmative vote of a majority of the votes cast in such director's election to promptly tender his or her resignation to the board, which resignation may be accepted or rejected by the board of directors after an evaluation of the relevant facts and circumstances, (iii) designate Delaware as the exclusive forum for adjudication of disputes and (iv) effect certain other changes. These changes are set forth in a document showing the effect of the revisions being effected by the adoption of the Amended Bylaws, which is attached as Exhibit 3.1 to this report, and the full text of the Amended Bylaws is set forth in Exhibit 3.2 attached to this report, each of which is incorporated by reference to this Item 5.03 and which qualifies the foregoing description in its entirety.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished herewith: Exhibit Number Description 3.1 Amendments to Second Amended and Restated Bylaws of the Company 3.2 Fourth Amended and Restated Bylaws of the Company 104 Cover Page Interactive Data File (the cover page XBRL tags are imbedded in the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fortress Biotech, Inc. (Registrant) Date: June 25, 2024 By: /s/ Lindsay A. Rosenwald, M.D. Lindsay A. Rosenwald, M.D. Chairman, President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR